Corrigendum to âEuropean contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS)â [Redox Biol. 13 (2017) 94â162]

Autor: J. Egea, I. Fabregat, Y.M. Frapart, P. Ghezzi, A. Görlach, T. Kietzmann, K. Kubaichuk, U.G. Knaus, M.G. Lopez, G. Olaso-Gonzalez, A. Petry, R. Schulz, J. Vina, P. Winyard, K. Abbas, O.S. Ademowo, C.B. Afonso, I. Andreadou, H. Antelmann, F. Antunes, M. Aslan, M.M. Bachschmid, R.M. Barbosa, V. Belousov, C. Berndt, D. Bernlohr, E. Bertrán, A. Bindoli, S.P. Bottari, P.M. Brito, G. Carrara, A.I. Casas, A. Chatzi, N. Chondrogianni, M. Conrad, M.S. Cooke, J.G. Costa, A. Cuadrado, P. My-Chan Dang, B. De Smet, B. Debelec-Butuner, I.H.K. Dias, J.D. Dunn, A.J. Edson, M. El Assar, J. El-Benna, P. Ferdinandy, A.S. Fernandes, K.E. Fladmark, U. Förstermann, R. Giniatullin, Z. Giricz, A. Görbe, H. Griffiths, V. Hampl, A. Hanf, J. Herget, P. Hernansanz-Agustín, M. Hillion, J. Huang, S. Ilikay, P. Jansen-Dürr, V. Jaquet, J.A. Joles, B. Kalyanaraman, D. Kaminskyy, M. Karbaschi, M. Kleanthous, L.O. Klotz, B. Korac, K.S. Korkmaz, R. Koziel, D. KraÄun, K.H. Krause, V. KÅen, T. Krieg, J. Laranjinha, A. Lazou, H. Li, A. Martínez-Ruiz, R. Matsui, G.J. McBean, S.P. Meredith, J. Messens, V. Miguel, Y. Mikhed, I. Milisav, L. MilkoviÄ, A. Miranda-Vizuete, M. MojoviÄ, M. Monsalve, P.A. Mouthuy, J. Mulvey, T. Münzel, V. Muzykantov, I.T.N. Nguyen, M. Oelze, N.G. Oliveira, C.M. Palmeira, N. Papaevgeniou, A. PaviÄeviÄ, B. Pedre, F. Peyrot, M. Phylactides, G.G. Pircalabioru, A.R. Pitt, H.E. Poulsen, I. Prieto, M.P. Rigobello, N. Robledinos-Antón, L. Rodríguez-Mañas, A.P. Rolo, F. Rousset, T. Ruskovska, N. Saraiva, S. Sasson, K. Schröder, K. Semen, T. Seredenina, A. Shakirzyanova, G.L. Smith, T. Soldati, B.C. Sousa, C.M. Spickett, A. Stancic, M.J. Stasia, H. Steinbrenner, V. StepaniÄ, S. Steven, K. Tokatlidis, E. Tuncay, B. Turan, F. Ursini, J. Vacek, O. Vajnerova, K. Valentová, F. Van Breusegem, L. Varisli, E.A. Veal, A.S. Yalçın, O. Yelisyeyeva, N. ŽarkoviÄ, M. Zatloukalová, J. Zielonka, R.M. Touyz, A. Papapetropoulos, T. Grune, S. Lamas, H.H.H.W. Schmidt, F. Di Lisa, A. Daiber

Publikováno v: Redox Biology, Vol 14, Iss , Pp 694-696 (2018)

Externí odkaz: https://doaj.org/article/4f3aaa00fa9044048a5a2e6b7c0610f0

Empagliflozin rescues primary murine cardiac fibroblasts, but not cardiomyocytes, from hypoxia-reoxygenation injury through STAT3-mediated cascades

Autor: N Mylonas, P Efentakis, P E Nikolaou, S Zerikiotis, M P Pieper, G Dimitriadis, E K Iliodromitis, I Andreadou

Publikováno v: European Heart Journal. 43

Introduction Empagliflozin (EMPA) is a selective sodium glucose co-transporter 2 inhibitor (SGLT2i) and an established drug against type 2 diabetes mellitus. Cardiovascular clinical outcome trials on EMPA have shown a reduced mortality rate related t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::33db5a01f8969b25289937fd4c9b5887
https://doi.org/10.1093/eurheartj/ehac544.2684

Endothelial dysfunction due to decreased nitric oxide bioavailability in dysglycaemic subjects and first-degree relatives of type 2 diabetic patients

Autor: I Ikonomidis, G Pavlidis, M Tsoumani, F Kousathana, K Katogiannis, D Tsilivarakis, J Thymis, A Kountouri, E Korakas, L Pliouta, J Parissis, A Bamias, G Filippatos, I Andreadou, V Lambadiari

Publikováno v: European Heart Journal. 43

Background/Introduction Oxidative stress plays an important role in the pathogenesis of type 2 diabetes mellitus. Purpose We aimed to investigate oxidative stress and nitrites/nitrates concentrations at baseline and during postprandial hyperglycaemia

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ae775fafa6a624f6100b9ccae1ac5787
https://doi.org/10.1093/eurheartj/ehac544.2413

Understanding the molecular mosaic of cardiotoxicity of light chains in plasma cell dyscrasias and cardiac light chain amyloidosis with the use of patient derived full-length light chains

Autor: P E Nikolaou, A Georgoulis, C Liacos, M Makridakis, P Efentakis, G Baltatzis, B Mavroidi, M Pelecanou, A Vlachou, E Terpos, C E Vorgias, M A Dimopoulos, E Kastritis, I Andreadou

Publikováno v: European Heart Journal. 43

Background Cardiac light chain amyloidosis (AL-CA) is a life-threatening disease and the major determinant of prognosis in AL amyloidosis. The management of heart failure (HF) in AL is challenging and gold standard therapies for HF are poorly tolerat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d3e45638295fc43b4817bb62299c4f1f
https://doi.org/10.1093/eurheartj/ehac544.2987

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.